

Do Not Enter

/RJH/

07/14/2009

AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions, and listings, of claims in the application:

1. **(Currently amended)** A method of inhibiting angiogenesis in treating a host with an angiogenic disease, comprising consisting essentially of contacting said host with a cephalotaxine in an amount sufficient to inhibit angiogenesis associated with said angiogenic disease, wherein said angiogenic disease is not a solid tumor and wherein said angiogenesis associated with said angiogenic disease is inhibited in said host.
2. **(Currently amended)** The method of claim 1 wherein the angiogenic disease is selected from the group consisting of an inflammatory disease, diabetic retinopathy, or macular degeneration, angiofibroma, neovascular glaucoma, arteriovenous malformation, nonunion fracture, connective tissue disorder, Osler-Weber syndrome, atherosclerotic plaque, psoriasis, corneal graft neovascularization, Pyogenic granuloma, retrobulbar fibroplasia, scleroderma, granulations, hemangioma, trachoma, hemophilic joints and vascular adhesions.
3. **(Original)** The method of claim 2 wherein the inflammatory disease is selected from the group consisting of rheumatoid arthritis, osteoarthritis, asthma, and pulmonary fibrosis.
4. **(Currently amended)** The method of claim 1 wherein the cephalotaxine comprises homoharringtonine (cephalotaxine, 4-methyl-2-hydroxy-2-(4-hydroxy-4-methylpentyl) butanedio[[c]]ate ester).
5. **(Currently amended)** The method of claim 1 wherein the cephalotaxine comprises a compound of the formula